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Sirolimus and Everolimus Induce Endothelial
Cellular Senescence Via Sirtuin 1 Down-Regulation
Therapeutic Implication of Cilostazol
After Drug-Eluting Stent Implantation
Hidetaka Ota, MD, PHD, Masato Eto, MD, PHD, Junya Ako, MD, PHD, Sumito Ogawa, MD, PHD,
Katsuya Iijima, MD, PHD, Masahiro Akishita, MD, PHD, Yasuyoshi Ouchi, MD, PHD
Tokyo, Japan
Objectives The aim of this study was to compare the effects of paclitaxel, sirolimus, and everolimus on the senescent phe-
notype in human endothelial cells, and to further investigate possible involvement of mammalian sirtuin 1
(Sirt1) down-regulation as a mechanism.
Background Endothelial cell senescence may play a role in impaired re-endothelialization after drug-eluting stent (DES) im-
plantation. Recently, the down-regulation of Sirt1 has been shown to mediate oxidative stress-induced endothe-
lial senescence.
Methods Senescent human umbilical vein endothelial cells (HUVEC) were judged by senescence-associated
-galactosidase assay (SA-gal), morphological appearance, and plasminogen activator inhibitor (PAI)-1.
Results Treatment with paclitaxel, sirolimus, and everolimus significantly caused a senescent phenotype and PAI-1 up-
regulation, associated with a decrease in endothelial nitric oxide synthase (eNOS) and Sirt1 expression. Overexpres-
sion of Sirt1 or Sirt1 activation reversed the sirolimus- or everolimus-induced senescent phenotype. Interestingly,
paclitaxel-induced senescence was not suppressed by Sirt1 overexpression, suggesting the existence of a different
mechanism. Cilostazol markedly inhibited the sirolimus- or everolimus-induced senescent phenotype (sirolimus or
everolimus [2.5 nmol/l]; 49.2% or 53.0% SA-gal positive vs. only 13.6% or 14.6% with cilostazol [100 mol/l]) and
PAI-1 up-regulation, but had no influence on the effects of paclitaxel. Finally, aspirin significantly blunted sirolimus- or
everolimus-induced senescence, but neither ticlopidine nor clopidogrel had any effects.
Conclusions Sirolimus and everolimus induce endothelial senescence involving down-regulation of Sirt1. In contrast, the devel-
opment of endothelial senescence by paclitaxel involves a Sirt1-independent pathway. Because sirolimus and everoli-
mus are involved in Sirt1 modulation, cilostazol rescues HUVEC from sirolimus- or everolimus-induced senescence.
These results may have therapeutic implications in the clinical sequelae after DES implantation. (J Am Coll Cardiol
2009;53:2298–305) © 2009 by the American College of Cardiology Foundation











recause of the marked reduction in restenosis rate, drug-
luting stent (DES) implantation has been the mainstay of
ercutaneous coronary interventions. Recent real-world ex-
eriences, however, have raised concern over a possible
ncrease in the frequency of late stent thrombosis (ST),
ccurring more than 1 year after stent implantation (1).
athological studies have shown that a lack or delay of
ndothelial healing plays an important role in the patho-
enesis of ST (2).
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Manuscript received October 19, 2008; revised manuscript received December 17,
008, accepted January 27, 2009.Endothelial senescence has been proposed to be involved
n endothelial dysfunction, atherogenesis, and thrombosis
3). Drugs used for DES, including paclitaxel and limus
amily members (e.g., sirolimus, everolimus), inhibit the
rowth of endothelial cells, possibly leading to endothelial
enescence and delayed re-endothelialization. However, the
ffect of such drugs on endothelial cell senescence has not
een well documented.
Mammalian sirtuin 1 (Sirt1), the closest homolog of
ilent information regulator 2, regulates the cell cycle,
enescence, apoptosis, and metabolism by interacting
ith a number of molecules, including p53, promyelocytic
eukemia protein, and peroxisome proliferators-activated
eceptor  (4–6). Sirt1 has been recognized as a key
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). Recently, we reported that an antiplatelet drug, cilosta-
ol, inhibited oxidative stress-induced endothelial senes-
ence through up-regulation of Sirt1 (10).
The aims of this study were to compare the effects of
aclitaxel, sirolimus, and everolimus on the senescent phe-
otype in human endothelial cells and to further investigate
he possible involvement of Sirt1 down-regulation as a
echanism. Potential protective effects of cilostazol and other
idely used antiplatelet drugs (aspirin, ticlopidine, and clopi-
ogrel) were also investigated.
ethods
aterials. Sirolimus and resveratrol were purchased from
ako Chemical Industries, Ltd. (Tokyo, Japan). Aspirin,
iclopidine, clopidogrel, paclitaxel, and everolimus were from
igma (St. Louis, Missouri). 8-hydroxydeoxyguanosine (8-
HdG, AB5830) was from Chemicon (Temecula, Califor-
ia). Cilostazol was provided by Otsuka Pharmaceutical Co.,
td. (Tokyo, Japan).
ell culture. Human umbilical vein endothelial cells
HUVEC) were purchased from Cambrex (Walkersville,
aryland), and maintained in endothelial growth medium
EGM-2) (EGM-2 single-quots, Cambrex). Population
oubling levels were calculated as described previously (11),
nd all experiments were performed at population doubling
evel of 8 to 9.
Figure 1 Paclitaxel, Sirolimus, and Everolimus Induced a Prema
Paclitaxel, sirolimus, and everolimus (2.5, 5 nmol/l) induced a premature senescent p
vs. control, n  3) and morphological changes (B). HUVEC  human umbilical veiransform from ticlopidine
nd clopidogrel into liver me-
abolites. Human liver micro-
omes were purchased from BD
entest (Woburn, Massachu-
etts). As described by Savi et al.
12), liver microsomes were ad-
usted to 0.75 mg protein/ml in
00 mmol/l potassium phosphate
uffer, pH 7.4, containing 100
mol/l potassium fluoride and 10
mol/l glutathione. Ticlopidine
nd clopidogrel were added at a
nal concentration of 1 mmol/l,
nd the reaction was initiated with
mmol/l -nicotinamide adenine
inucleotide phosphate. Incuba-
ion was carried out at 37°C under
ontinuous stirring (100 rpm) and
rotection from light using a re-
iprocal incubator. After 60 min,
he incubation medium was cooled to 4°C and centrifuged at
0,000 g for 10 min, and supernatants were collected.
enescence-associated -galactosidase (SA-gal) assay.
he HUVEC were grown in 100-mm collagen-coated
ishes to 80% confluence. They were pre-treated with
ehicle (0.05% dimethylsulfoxide), cilostazol (10, 30, 100
Senescent Phenotype
ype in HUVEC as judged by SA-gal (A) (unpaired t test, *p  0.05
thelial cells; SA-gal  senescence-associated -galactosidase assay.
Abbreviations
and Acronyms
DES  drug-eluting stent(s)
EGM  endothelial growth
medium
eNOS  endothelial nitric
oxide synthase
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information regulation 2
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00 mol/l), clopidogrel (10, 30, 100 mol/l), or resveratrol
10, 30, 100 mol/l) diluted in EGM-2 medium for 24 h.
itric oxide production was induced with calcium A 23187
Figure 2 Expression of PAI-1, eNOS, and Sirt1 After Treatment
Expression of PAI-1 (A), eNOS, and Sirt1 (B) at 10 days after treatment with pacli
cell lysates (20 g) were prepared from treated HUVEC. Similar results were obse
plasminogen activator inhibitor-1; Sirt1  silent mating type information regulation
Figure 3 Overexpression of Sirt1 Inhibited Sirolimus- and Evero
Overexpression of Sirt1 (A) or treatment with resveratrol (10, 30, 100 mol/l) inh
as judged by SA-gal (B) (unpaired t test, *p  0.05 vs. control, n  3) and morponophore (Sigma, 1 mol/l) followed under incubation
ith aspirin, cilostazol, ticlopidine, or clopidogrel for 20
in (n  3 samples in each experiment). The HUVEC
ere washed 3 times with EGM-2 and then treated for 24 h
Paclitaxel, Sirolimus, or Everolimus
sirolimus, or everolimus (2.5 nmol/l) were analyzed by Western blotting. Whole-
3 independent experiments. eNOS  endothelial nitric oxide synthase; PAI-1 
olog 1.
-Induced Senescent Phenotype
sirolimus- and everolimus-induced senescent phenotype
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June 16, 2009:2298–305 Therapeutic Implication of Cilostazol for DESith paclitaxel, sirolimus, or everolimus (5 nmol/l) diluted
n EGM-2. After the treatment, HUVEC were trypsinized,
eseeded at a density of 1  105 in 60-mm dishes, and
ultured in EGM-2 containing these compounds (cilosta-
ol, aspirin, ticlopidine, or clopidogrel) for 10 days. At 10
ays after treatment with paclitaxel, sirolimus, or everoli-
us, HUVEC were fixed and the proportion of SA-gal
ositive cells was determined as described by Dimri et al. (13).
irt1 overexpression. The Sirt1 was overexpressed by
ransfection with pIRES-Sirt1 (10 g), which was provided
y Dr. R. A. Weinberg (4,14), using jetPEI-HUVEC
Polyplustransfection, Illkirch, France) according to the
anufacturer’s instructions. At 3 days after transfection,
UVEC were treated with sirolimus, everolimus, or pacli-
axel (2.5 nmol/l) for 24 h, washed 3 times with medium,
nd cultured for up to 10 days.
mmunoblotting. Cells were lysed on ice for 1 h in buffer
50 mmol/l Tris-HCl, pH 7.6, 150 mmol/l NaCl, 1%
P-40, 0.1% sodium dodecyl sulfate [SDS], 1 mmol/l
ithiothreitol, 1 mmol/l sodium vanadate, 1 mmol/l phe-
ylmethylsulfonyl fluoride, 10 g/ml aprotinin, 10 g/ml
eupeptin, and 10 mmol/l sodium fluoride). Equal amounts
f protein were separated by SDS-polyacrylamide gel elec-
rophoresis and transferred to nitrocellulose membranes.
fter blocking, the filters were incubated with the following
ntibodies; anti-endothelial nitric oxide synthase (eNOS)
BD Transduction Laboratories, Franklin Lakes, New Jer-
ey), anti-Sirt1 (Santa Cruz Biotechnology, Inc., Santa
ruz, California), anti-plasminogen activator inhibitor-1
PAI-1) (Molecular Innovations, Inc.) and anti–-actin
Sigma). After washing and incubation with horseradish
Figure 4 Effect of Cilostazol on Paclitaxel-, Sirolimus-, or Evero
Effect of cilostazol (10, 30, 100 mol/l) on paclitaxel-, sirolimus-, or everolimus (2
SA-gal (A) (unpaired t test, *p  0.05 vs. control, n  3) and morphological chaeroxidase-conjugated antirabbit or antimouse immuno-
lobulin G (Amersham, Piscataway, New Jersey) for 1 h,
he antigen–antibody complexes were visualized using an
nhanced chemiluminescence system (Amersham).
ata analysis. Values are shown as mean  SEM in the
ext and figures. Unpaired Student t test was used for
tatistical analysis. Probability values0.05 were considered
ignificant.
esults
aclitaxel, sirolimus, and everolimus induce premature
enescence in human endothelial cells. To investigate the
ffect of paclitaxel, sirolimus, and everolimus on the endo-
helial senescent phenotype, we treated HUVEC with each
rug for 24 h. Treatment with paclitaxel, sirolimus, and
verolimus significantly induced a senescent phenotype as
udged by SA-gal and an enlarged, flattened cell morpho-
ogical appearance at 10 days (Figs. 1A and 1B). Of note,
aclitaxel had a tendency to arrest senescent growth, asso-
iated with round colony formation, because it may have the
bility to stabilize microtubules and inhibit cell division.
ffects of paclitaxel, sirolimus, and everolimus on PAI-1,
NOS, and Sirt1 expression in human endothelial cells.
lasminogen activator inhibitor-1 is a potent inhibitor of
brinolysis and a mediator of thrombosis, and its expression
an also be used as a marker of endothelial senescence (15).
n parallel with SA-gal, expression of PAI-1 was increased
y treatment with paclitaxel, sirolimus, and everolimus (Fig.
A). Both eNOS and Sirt1 play a pivotal role in endothelial
unction and senescence (8–16); therefore, we examined
-Induced Senescent Phenotype
ol/l)-induced senescent phenotype as judged by
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us, and everolimus decreased the expression of eNOS and
irt1.
verexpression of Sirt1 and resveratrol inhibited
irolimus- and everolimus-induced senescent phenotype.
o clarify the molecular mechanisms of regulation of
ndothelial senescence induced by paclitaxel, sirolimus, and
verolimus, we induced Sirt1 gene overexpression and per-
ormed treatment with resveratrol, a Sirt1 chemical activa-
or. We confirmed overexpression of Sirt1 at the protein
evel (Fig. 3A). As shown in Figures 3B and 3C, overex-
ression of Sirt1 and resveratrol decreased SA-gal–positive
ells and specific morphological senescent changes induced
y sirolimus and everolimus. Unexpectedly, paclitaxel-
reated cells could not be restored from a senescent pheno-
ype. These results indicate that Sirt1 is a key molecule in
he modulation of sirolimus- and everolimus- but not
aclitaxel-induced senescence of HUVEC.
ilostazol inhibits sirolimus- or everolimus-induced pre-
ature senescence. We examined the effect of cilostazol
n a senescent phenotype in human endothelial cells. We
re-treated HUVEC with cilostazol for 24 h before the
ddition of paclitaxel, sirolimus, or everolimus. Treatment
ith cilostazol inhibited the senescent phenotype induced
y sirolimus or everolimus at 10 days (Fig. 4A). Under
reatment with sirolimus or everolimus (2.5 nmol/l), 49.2%
r 53.0% of cells were SA-gal positive, versus only 13.6%
Figure 5 Expression of PAI-1, eNOS, and Sirt1 When HUVEC W
Expression of PAI-1 (A), eNOS, and Sirt1 protein (B) at 10 days when HUVEC were
everolimus, or paclitaxel (2.5 nmol/l). Whole-cell lysates (20 g) were prepared fro
viations as in Figures 1 and 2.r 14.6% of cilostazol (100 mol/l)-treated cells under the
ame conditions. Treatment with cilostazol decreased the
pecific senescent morphological changes and expression
f PAI-1 induced by sirolimus and everolimus as well
Figs. 4B and 5A). Human umbilical vein endothelial cells
reated with paclitaxel did not show a reduction of the
enescent phenotype by treatment with cilostazol (Figs. 4A
nd 5A). At the same time, we checked the effect of other
ntiplatelet drugs (aspirin, ticlopidine, and clopidogrel) on
he senescent phenotype (Figs. 5A and 6). Treatment with
spirin decreased SA-gal–positive cells and expression of
AI-1, but treatment with ticlopidine or clopidogrel did not
ave any effect on them. To evaluate potential clinical
nteractions of ticlopidine and clopidogrel on endothelial
enescence, we next used these compounds after incubation
ith human hepatic microsomes. Treatment with metabo-
ites of ticlopidine and clopidogrel did not decrease the
aclitaxel-, sirolimus-, or everolimus-induced senescent
henotype (paclitaxel, sirolimus, everolimus [2.5 nmol/l];
1.4%, 55.7%, or 53.5% SA-gal positive vs. 64.9%/62.2%,
5.9%/54.6%, or 55.8%/54.7% with metabolites of ticlopi-
ine/clopidogrel [100 mol/l]).
reatment with cilostazol reversed eNOS and Sirt1
xpression. To explore the mechanism by which cilostazol
revented premature endothelial senescence induced by siroli-
us and everolimus, we examined whether they could promote
NOS and the longevity gene, Sirt1. Cilostazol and aspirin
reated With Cilostazol, Aspirin, Ticlopidine, or Clopidogrel
ed with cilostazol, aspirin, ticlopidine, or clopidogrel after addition of sirolimus,
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June 16, 2009:2298–305 Therapeutic Implication of Cilostazol for DESignificantly increased eNOS and Sirt1 protein at 10 days after
reatment with sirolimus or everolimus (Fig. 5B). Although
ilostazol and aspirin did not inhibit a paclitaxel-induced
enescent phenotype, it reversed eNOS and Sirt1 expression
Fig. 5B). Moreover, treatment with cilostazol or aspirin
ecreased 8-OHdG, a marker of oxidative stress (Fig. 7).
iscussion
n the present study, we found that paclitaxel, sirolimus, and
verolimus significantly induced endothelial senescence,
ith decreased eNOS and Sirt1 expression. Endothelial cell
Figure 6 Effect of Aspirin, Ticlopidine, and Clopidogrel on Pacli
Effect of aspirin (asp), ticlopidine (ticlo), and clopidogrel (clopi) (10, 30, 100 mo
(2.5 nmol/l)-induced senescent phenotype as judged by SA-gal (unpaired t test, *
Figure 7 Antioxidative Effect of Cilostazol, Aspirin, Ticlopidine,
Effect of cilostazol, aspirin, ticlopidine, and clopidogrel (10, 30, 100 mol/l) on s
by immunofluorescent cell staining for 8-hydroxydeoxyguanosine (8-OHDG) (green)enescence induced by sirolimus or everolimus was partly
lunted by Sirt1 overexpression or Sirt1 activation by
esveratrol, whereas senescence induced by paclitaxel oc-
urred through a Sirt1-independent pathway.
Drug-eluting stents significantly reduce the rate of
estenosis, but several pre-clinical and clinical safety
oncerns (17,18) related to its use have been expressed.
ne of the most important issues raised is ST, which is
artly caused by delayed re-endothelialization. However,
he pathogenesis of re-endothelialization or ST has not
et been fully explored (19), and evaluation of the degree
-, Sirolimus-, or Everolimus-Induced Senescent Phenotype
paclitaxel-, sirolimus-, or everolimus
.05 vs. control, n  3). Abbreviations as in Figure 1.
Clopidogrel on Sirolimus-Induced Senescent Phenotype
s (2.5 nmol/l)-induced senescent phenotype as judged
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s of great significance.
First, we showed that paclitaxel, sirolimus, and everoli-
us significantly induced endothelial senescence, in associ-
tion with reduced eNOS and increased PAI-1 expression,
hich are implicated in endothelial dysfunction and throm-
ogenesis. Similar to our results, recent studies showed that
irolimus increased tissue factor expression (1,20), and that
oth sirolimus and paclitaxel selectively increased PAI-1
xpression (21). Secondly, we showed that overexpression of
irt1 reversed the sirolimus- or everolimus-induced senes-
ent phenotype. Interestingly, paclitaxel-induced senescence
as not suppressed by Sirt1 overexpression. These results
uggest that paclitaxel, sirolimus, and everolimus induce
ndothelial senescence through 2 distinct pathways, and
irolimus- and everolimus-induced senescence is mainly
egulated by Sirt1. In addition to these findings, treatment
ith cilostazol reversed the senescent phenotype induced by
irolimus or everolimus, but not paclitaxel. As previously
eported, cilostazol activates protein kinase A and PI3K/
kt signaling and increases eNOS expression (22). Re-
ently, we reported that cilostazol inhibited oxidative stress–
nduced premature senescence via up-regulation of Sirt1 in
uman endothelial cells (10). These results imply that nitric
xide production by cilostazol increases Sirt1 expression,
nd increased Sirt1 expression inhibits endothelial senes-
ence. Therefore, the eNOS–Sirt1 axis may play an impor-
ant role in the modulation of sirolimus- or everolimus-
nduced premature senescence. Although cilostazol reversed
NOS and Sirt1 expression in HUVEC treated with pac-
itaxel, cilostazol did not rescue HUVEC from a senescent
henotype. Paclitaxel inhibits cell proliferation by promot-
ng polymerization of tubulin dimers and subsequently
tabilizing microtubules into an assembled state, which
locks the cell cycle from G2 to M phase. In contrast,
irolimus and everolimus bind to FKBP12 and subsequently
ind to the mammalian target of rapamycin. This complex
hen increases cellular cyclin-dependent kinase inhibitor
27 and decreases the phosphorylation of retinoblastoma
rotein, which blocks the cell cycle from G1 to S phase (23).
s previously reported (24), microtubules are not substrates
f Sirt1. Because paclitaxel strongly stabilizes microtubules
nd inhibits cell division, we speculate that increased Sirt1
xpression was insufficient for reversal of the paclitaxel-
nduced senescent phenotype, or there might be other
egulators.
Resveratrol exerted a significant effect at a concentration
f 100 mol/l (Fig. 3), which seems a relatively high
oncentration to achieve in vivo. However, considering that
ovel small molecule activators of Sirt1, even 1,000-fold
ore potent than resveratrol, are being identified (Sirtris
harmaceuticals Inc., Boston, Massachusetts) (25), we sug-
est that using these chemical agents to activate Sirt1 might
e of potential therapeutic value for protection against
ndothelial senescence.In the current study, the impact of cilostazol in reducing
ost-operative sequelae seemed more marked in sirolimus-
luting stents (SES) than in paclitaxel-eluting stents. More-
ver, SES plus triple treatment reduced restenosis more
han did SES plus standard dual treatment (26). Cilostazol
ot only is an antiplatelet drug, but also has pleiotropic
ffects, including a vasodilating action, endothelial cell
rotection, and improvement of lipid metabolism (27–29).
owever, the impact of cilostazol on endothelial senescence
fter DES implantation has not been reported. Based on
his study, we emphasize that cilostazol might have favor-
ble effects against endothelial senescence when adminis-
ered with sirolimus or everolimus, through up-regulation of
irt1. To assess the implications of our findings, further
tudies are needed to examine the degree of senescence as
ell as the expression pattern of Sirt1 in the arterial wall
fter deployment of DES in vivo.
onclusions
ur study shows that paclitaxel, sirolimus, and everolimus
nduce endothelial senescence through 2 distinct pathways.
he development of endothelial senescence induced by
irolimus and everolimus is Sirt1-dependent, whereas pac-
itaxel acts through a Sirt1-independent pathway. Because
irolimus and everolimus (limus family) were involved in
irt1 modulation, cilostazol reversed sirolimus- or
verolimus-induced senescence. Our results may have an
nteresting clinical implication that triple antiplatelet ther-
py has more beneficial effects on endothelial senescence
han has standard dual therapy of SES and everolimus-
luting stents.
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